Compare Dicks Sporting Goods Inc (DKS) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dicks Sporting Goods Inc vs Merck & Co., Inc. — how do they compare? Dicks Sporting Goods Inc trades at $134.69 (market cap $13.26B), while Merck & Co., Inc. trades at $142.89 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 26.5× Dicks Sporting Goods Inc's market cap, and Dicks Sporting Goods Inc pays the higher dividend (3.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dicks Sporting Goods Inc for 19 Days and Merck & Co., Inc. for 98 Days on average.
| DKS | MRK | |
|---|---|---|
Market Cap | $13.26B | $351.28B |
Volume | 2,292,035 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $239.17 | $156.43 |
52-Week Low | $121.15 | $82.49 |
Typical Hold Time | 19 Days | 98 Days |
Enterprise Value | $20.31B | $398.04B |
Dividend Yield | 3.71% | 2.39% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DICK'S Sporting Goods (DKS) trades at $131.18, down 2.74% on the day, amid a bearish technical signal and ongoing securities class action news. The stock shows mixed fundamentals with a trailing P/E of 14.86 and P/S of 0.57, while recent earnings beat estimates in two of the last three quarters. Revenue grew to $13.44B in 2025, though net income margin compressed to 3.97% in 2026 trends. Analyst consensus remains positive with a $153.30 price target and 57% buy ratings, but legal overhangs and a negative cash flow trend present headwinds.
The investment case balances attractive valuation multiples against significant litigation risks and weakening profitability. Upside exists if the company navigates legal challenges and stabilizes margins, but the bearish technical setup and negative investor sentiment suggest caution. The stock's near-term direction will likely hinge on Q3 2026 earnings results and developments in the class action lawsuit.
Merck (MRK) trades at $142.79, up 0.61% on the day, with a bearish technical signal despite beating earnings estimates in recent quarters. The company reported 2025 revenue of $65.01B and net income of $18.25B, with a high P/E ratio of 113.9 reflecting premium valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, while institutional investors have been increasing stakes.
The outlook is mixed: strong analyst consensus (68% buy ratings) and a $158.78 price target suggest upside, but high valuation and bearish technicals pose near-term risks. Key opportunities include pipeline expansion via M&A; risks involve integration challenges and patent pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dicks Sporting Goods Inc
Dick's Sporting Goods is a leading omni-channel sporting goods retailer in the US It offers an extensive assortment of authentic sports equipment, apparel, footwear, and accessories through its stores and digital platforms.
Read more on DKS →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
